Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8328754 | 0.71 | GBA1 (0.41) | — | |
| SCHEMBL1017992 | 0.71 | PTK2 (0.38) | — | |
| SCHEMBL7798852 | 0.71 | KMT2A (0.43) | — | |
| SCHEMBL31387537 | 0.70 | HTR7 (0.33) | — | |
| SCHEMBL19207125 | 0.70 | HTR7 (0.33) | — | |
| SCHEMBL29918724 | 0.67 | — | — | |
| SCHEMBL424656 | 0.67 | — | — | |
| SCHEMBL22090385 | 0.67 | APLNR (0.30) | APLNR | |
| SCHEMBL30989664 | 0.67 | KDM4E (0.40) | — | |
| SCHEMBL1019206 | 0.67 | NPC1 (0.45) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688155-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | Bial-Portela & CA, S.A. (PT) | 2026-02-11 | — | — | EP | disclosed |
| US-12415795-B2 | 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | NXERA PHARMA UK LIMITED (GB) | 2025-09-16 | — | — | US | disclosed |
| WO-2025023852-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | disclosed |
| US-12006316-B2 | 9H-pyrrolo-dipyridine derivatives | UCB Biopharma SRL (BE) | 2024-06-11 | — | — | US | disclosed |
| US-20240092754-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | NXERA PHARMA UK LIMITED (GB) | 2024-03-21 | — | — | US | disclosed |
| US-11680053-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-06-20 | — | — | US | disclosed |
| US-11584732-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-20220213103-A1 | 9H-PYRROLO-DIPYRIDINE DERIVATIVES | UCB Biopharma SRL (BE) | 2022-07-07 | — | — | US | disclosed |
| US-11312716-B2 | 9H-pyrrolo-dipyridine derivatives | UCB Biopharma SRL | 2022-04-26 | — | — | US | disclosed |
| US-20220056009-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | NXERA PHARMA UK LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| EP-1379525-B1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMA INC (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7112595-B2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| EP-1679313-A2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| EP-1379525-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213103-A1 | 9H-PYRROLO-DIPYRIDINE DERIVATIVES | MAPT, PSEN1, PRNP | GRM5 1027/4885APLNR 1266/4885ACHE 636/4885 |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | GRM5 8/4885APLNR 144/4885ACHE 751/4885 |
| US-11680053-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | GRM5, GRM2, GRM6 | GRM5 1/4885APLNR 405/4885ACHE 585/4885 |
| US-11584732-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | GRM5, GRM2, GRM6 | GRM5 1/4885APLNR 405/4885ACHE 585/4885 |
| US-12006316-B2 | 9H-pyrrolo-dipyridine derivatives | MAPT, PSEN1, PRNP | GRM5 1027/4885APLNR 1266/4885ACHE 636/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | GRM5 8/4885APLNR 144/4885ACHE 751/4885 |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | GRM5 8/4885APLNR 144/4885ACHE 751/4885 |
| US-11312716-B2 | 9H-pyrrolo-dipyridine derivatives | MAPT, PSEN1, PRNP | GRM5 1027/4885APLNR 1266/4885ACHE 636/4885 |
| US-12415795-B2 | 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | GRM5, GRM6, GRM2 | GRM5 1/4885APLNR 367/4885ACHE 817/4885 |
| US-20240092754-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | GRM5, GRM6, GRM2 | GRM5 1/4885APLNR 367/4885ACHE 817/4885 |
| US-20220056009-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | GRM5, GRM6, GRM2 | GRM5 1/4885APLNR 367/4885ACHE 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.